Today: 7 February 2026
Subscribe
Browse Category

Biotechnology News 30 October 2025 - 4 November 2025

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta (SRPT) Stock Collapses 80% on FDA Bombshell – Is a Big Rebound Coming?

SRPT Stock Price & Recent Performance Sarepta’s stock has experienced a dramatic collapse in 2025, wiping out years of gains. After starting the year near all-time highs, SRPT shares have plunged by over 80% year-to-datemarketbeat.com. As of early November 2025, the stock trades in the mid-teens, down from about $120–$130 at the start of the year. In fact, the stock’s 52-week range tells the story: it hit a high of $138.81 and a low of just $10.41 over the past yearmarketbeat.com. This implosion has vastly underperformed the biotech sector (for context, the biotech index is up ~19% in 2025) and
4 November 2025
····
Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Phio Pharmaceuticals (PHIO) Stock Skyrockets on Breakthrough Skin Cancer Trial Results – In-Depth Analysis & 2025 Outlook

Company Background and Business Model Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapies for cancer. The company was co-founded by Nobel laureate Dr. Craig Mello, a discoverer of RNAi, leveraging that legacy to develop its proprietary INTASYL™ gene-silencing technologyphiopharma.com. Originally known as RXi Pharmaceuticals (founded ~2011), Phio rebranded and refocused on immuno-oncology. Its mission is to use small interfering RNA (siRNA) to “silence” genes that allow tumors to evade the immune system, thereby empowering the body’s own defenses to fight cancerragingbull.com. Headquartered in Pennsylvania (King of Prussia) with R&D roots in Massachusetts, Phio is
3 November 2025
·····
UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

UniQure’s Roller-Coaster: Gene Therapy Breakthrough, FDA Setback, and What’s Next for QURE Stock

Stock Performance: Skyrockets and Crashes UniQure’s stock has been on a wild ride in 2025. After starting the year in the mid-teens, QURE shares skyrocketed through mid-2025 on hopes for its Huntington’s gene therapy. The rally hit a fever pitch in late September when Phase 1/2 trial data showed a remarkable 75% reduction in disease progression with AMT-130 – news that caused the stock to surge almost 200% that monthreuters.com. By late October, QURE was hovering around $68–$70, up roughly 300–500% from spring levels. However, in the past few days the stock’s momentum sharply reversed. On Monday, Nov 3, 2025,
3 November 2025
···
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Company Overview and Background Acrivon Therapeutics is a Boston-area biotech (NASDAQ: ACRV) founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicinestockanalysis.com. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3 (Acrivon Predictive Precision Proteomics), lies at the heart of this strategy. Using proteomics and AI tools, AP3 measures the activity of myriad proteins and signaling pathways inside tumor cells in their native state, rather than just analyzing DNA mutationsglobenewswire.comglobenewswire.com. This allows Acrivon
3 November 2025
···
Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Off-the-Shelf CAR-T Triumph: Caribou’s Breakthrough Results Spark Stock Surge

Caribou’s Game-Changing CAR-T Results Caribou Biosciences – a clinical-stage biotech focusing on genome-edited cell therapies – stunned the biotech world with new data on November 3, 2025, showcasing that its off-the-shelf CAR-T cell treatments can achieve remission rates on par with personalized CAR-T therapiesstatnews.com. In an early-morning webcast, Caribou revealed Phase 1 trial outcomes from two programs: vispa-cel for B-cell lymphoma and CB-011 for multiple myelomatipranks.com. The headline: patients with aggressive blood cancers, who had exhausted other options, responded remarkably well to these donor-derived CAR-T infusions. Caribou reported multiple complete and durable remissions in both trials, exceeding what many thought
3 November 2025
··
Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Premarket Shock: Why CRISPR Therapeutics Could Move Big Today

Current News Stock Price and Market Activity CRSP is trading around the mid-$60s ahead of Monday’s open. By Reuters (Nov 2) it was ~$64.04 (up +4.86% on the day) Reuters. (Nasdaq closes on Oct 31 showed ~$63.99 Reuters.) Over the past month CRSP has gained roughly 17% Genengnews, boosted by recent data releases. For example, a 3-day rally in mid-Oct lifted CRSP ~5% after the SyNTase/CTX460 results were announced Genengnews. Technical indicators are mixed: the 14-day RSI is ~50 (neutral) and the MACD is slightly negative Investing. Shorter moving averages (5/10/20-day around $63–$63.8) are giving buy signals Investing, but the
2 November 2025
·······
Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Illumina Stock Rockets 20%+ After Blowout Quarter – What’s Next for ILMN?

Stock Price & Recent Performance Illumina’s stock has whipsawed in late 2025. After drifting near its 52-week lows (~$69 in late 2024), it ticked up to the mid-$90s by mid-October 2025. Following the Oct. 30 earnings report, ILMN exploded higher: by Oct. 31 it was trading around $120 ts2.tech Marketbeat. (MarketBeat confirms ILMN closed $123.64 on 10/31, +24.9% for the day Marketbeat.) TS2.tech notes that the stock was “around the high $110s–$120 range” on Oct. 31, a sharp jump from the mid-$90s “just days prior” ts2.tech. The surge was driven by the earnings beat (see below) and raised guidance. In
1 November 2025
·····
Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Biotech Boom: Cabaletta Bio’s CAR-T Trial Sparks 40% Stock Surge

Stock Performance & Technical Indicators Cabaletta’s stock has been very volatile. From ~$2.40 on Oct 27 (post-data) it briefly dipped to the $2.47 area by Oct 30, then exploded higher on Oct 31. Benzinga notes that CABA “rose 36.6% to $3.38” intraday on Oct 31benzinga.com; it eventually closed at $3.61stockanalysis.com. Over the week of Oct 25–31, CABA gained ~37%tradingview.com. For perspective, its 52-week range is roughly $0.99–$5.46stockanalysis.com. Technically, the stock is strongly overbought after the rally. On Oct 31 the 14-day RSI was ~84investing.com (above 70 = overbought). All short-term moving averages (5d, 10d, 20d) sit well below the price
31 October 2025
···
Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Illumina Stock Surges on Genomics Breakthroughs – What’s Next for ILMN?

Q3 2025 Earnings: Beat Expectations and Lifted Guidance Illumina’s latest quarterly report (Q3 FY2025) provided a much-needed spark for investors. The San Diego-based genomics giant reported $1.084 billion in revenue for Q3, slightly above Wall Street estimates (~$1.07B) and flat versus the same quarter last yearinvesting.com. While flat growth might not sound impressive, it exceeded Illumina’s own guidance range, marking an improvement in a year where demand had been soft. Adjusted earnings were $1.34 per share, handily beating the ~$1.17 consensusinvesting.com. CEO Jacob Thaysen noted the team “delivered Q3 results that exceeded the high-end of our guidance… driven by revenue acceleration
31 October 2025
···
Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Guardant Health (GH) Stock Rockets on Earnings Beat and New Cancer-Screening Wins

Strong Q3 Earnings Propel Stock Higher Guardant’s latest quarterly report blew past Wall Street’s expectations, sparking a sharp rally in its shares. For Q3 2025, revenue was $265.2 million, a 39% jump from a year ago and well above the ~$235 million analysts had forecastinvesting.com. On an adjusted basis, Guardant lost $0.39 per share, much better than the roughly $0.79 loss expected. Management immediately lifted the full-year sales outlook to $965–970 million (about 31% growth)investors.guardanthealth.com, up from $915–925M previously. As a result, GH stock jumped nearly 30% in morning trading on Oct. 30 (to about $94, from ~$72 at Thursday’s
30 October 2025
···
Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

HBIO Stock in Freefall – and a Nasdaq Lifeline Harvard Bioscience’s share price has been on a wild ride in 2025, mostly downhill. The stock now hovers around 40 cents, down from the mid-$2 range a year agofintel.io. In fact, HBIO has lost nearly 84% of its value year-over-yearfintel.io, an astonishing collapse that reflects both company-specific struggles and the broader market rout in small-cap biotech names. Shares cratered to an intraday low of $0.28 in mid-2025 amid intense selling pressureinvesting.com, before staging a modest rebound. Even after some recovery, HBIO remains deep in penny stock territory, a far cry from
30 October 2025
···
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo’s counter-offer details Novo Nordisk’s proposal is unsolicited, meaning Metsera’s board and shareholders will now review it against Pfizer’s agreement. Novo emphasizes that Metsera’s experimental therapies would be “complementary” to its own obesity portfolioreuters.com. According to MarketScreener (Dow Jones Newswires), the bid is $56.50 in cash per Metsera share plus $21.25 in milestone CVRsmarketscreener.com. By contrast, Pfizer’s September deal was $4.9B upfront (about $28.50/share) plus CVRs, for up to ~$7.3Bts2.techreuters.com. Novo’s offer thus values the company at roughly $6.5B upfront, sweetened to ~$9B with earnouts. Novo’s CEO Maziar “Mike” Doustdar hailed the move as proof of the company’s ambition. In
30 October 2025
···
1 … 17 18 19 20 21 … 25

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop